Recommendation for Completing Pneumococcal Vaccination After PCV20 Dose
If a pediatric patient has received a dose of PCV20, the pneumococcal conjugate vaccine series should be completed with PCV20—do not switch to PCV10, PCV13, or PCV15. The principle is to complete the vaccination series using the same vaccine that was initiated.
Rationale and Evidence
Primary Principle: Same Vaccine Series Completion
The established guideline principle for pneumococcal conjugate vaccines is that children should complete their vaccination series with the same vaccine product used at initiation 1, 2. This approach ensures:
- Consistent serotype coverage throughout the series
- Predictable immunogenicity based on clinical trial data
- Optimal immune response without potential interference from switching formulations
Why Not Switch to PCV10?
PCV10 contains only 10 serotypes compared to PCV20's 20 serotypes. Switching from PCV20 to PCV10 would:
- Reduce serotype coverage by eliminating protection against 10 additional serotypes (1,3,5, 6A, 7F, 19A, 8, 10A, 11A, 12F, 15B, 22F, 33F)
- Compromise the vaccination series by not maintaining the broader protection initiated with PCV20
- Lack clinical trial data supporting this specific switch pattern
Why Not Switch to PCV13 or PCV15?
While historical ACIP guidelines addressed transitioning from PCV7 to PCV13 3, these recommendations were made in the context of upgrading to broader coverage, not downgrading. The 2010 ACIP guidelines specifically stated that "infants and children aged <24 months who have received ≥1 dose of PCV7 should complete the vaccination series with PCV13" 3—this was an upward transition to more comprehensive protection.
Switching from PCV20 to PCV13 or PCV15 would:
- Reduce serotype coverage (losing 7 or 5 serotypes respectively)
- Contradict the established principle of completing series with the same or superior vaccine
- Lack supporting immunogenicity data for this specific downgrade pattern
Practical Implementation
For Healthy Children
Complete the age-appropriate schedule with PCV20:
- Ages 2-6 months at first dose: Continue with 3 primary doses plus 1 booster (total 4 doses)
- Ages 7-11 months at first dose: Continue with 2 primary doses plus 1 booster (total 3 doses)
- Ages 12-23 months at first dose: Complete with 2 total doses, ≥8 weeks apart
- Ages 24-59 months at first dose: Single dose completes the series
For High-Risk Children
Children with underlying medical conditions (immunocompromising conditions, chronic heart/lung disease, CSF leaks, cochlear implants, sickle cell disease, asplenia) may require additional doses 3:
- Ages 24-71 months with <3 prior doses: 2 doses of PCV20, ≥8 weeks apart
- Ages 24-71 months with 3 prior doses: 1 additional dose of PCV20
Minimum Intervals
- For children <12 months: Minimum 4 weeks between doses
- For children ≥12 months: Minimum 8 weeks between doses 3
Important Caveats
Interchangeability Exception
Recent evidence suggests that PCV13, PCV15, and PCV20 can be used interchangeably in both healthy children and those at risk for invasive pneumococcal disease 4, 2. However, this interchangeability recommendation applies when:
- Supply issues necessitate switching
- The switch maintains or increases serotype coverage (e.g., PCV13→PCV15 or PCV13→PCV20)
The interchangeability does NOT support downgrading from PCV20 to lower-valent vaccines when PCV20 is available.
If PCV20 Is Unavailable
Only if PCV20 is genuinely unavailable should you consider:
- First choice: PCV15 (loses 5 serotypes but maintains 15)
- Second choice: PCV13 (loses 7 serotypes but maintains 13)
- Not recommended: PCV10 (loses 10 serotypes)
Document the reason for switching and ensure the child receives appropriate catch-up vaccination when PCV20 becomes available.
Clinical Bottom Line
Complete the PCV20 series with PCV20. The principle of series completion with the same vaccine, combined with the lack of data supporting downgrade transitions and the clear benefit of broader serotype coverage, makes continuing with PCV20 the only evidence-based recommendation. Switching to a lower-valent vaccine would compromise protection without any demonstrated benefit.